Prestige Consumer Healthcare (NYSE:PBH) was downgraded by investment analysts at Desjardins to a “hold” rating in a report issued on Wednesday. They presently have a $88.00 price target on the stock. Desjardins’ target price would indicate a potential upside of 202.41% from the stock’s current price.
A number of other research firms also recently issued reports on PBH. ValuEngine downgraded Prestige Consumer Healthcare from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 10th. Zacks Investment Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “sell” rating in a research report on Friday, February 1st. DA Davidson raised their price objective on Prestige Consumer Healthcare to $38.00 and gave the company a “neutral” rating in a research report on Monday, November 5th. Finally, Raymond James downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating and set a $28.40 price objective on the stock. in a research report on Tuesday, January 15th. Two research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Prestige Consumer Healthcare has a consensus rating of “Hold” and an average price target of $45.48.
PBH stock opened at $29.10 on Wednesday. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.34 and a current ratio of 2.28. Prestige Consumer Healthcare has a twelve month low of $26.25 and a twelve month high of $41.76. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 11.28, a price-to-earnings-growth ratio of 1.60 and a beta of 0.91.
Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 7th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.02. Prestige Consumer Healthcare had a return on equity of 11.85% and a net margin of 6.44%. The business had revenue of $241.40 million for the quarter, compared to the consensus estimate of $241.40 million. During the same quarter in the prior year, the company earned $0.70 EPS. The business’s revenue was down 10.8% compared to the same quarter last year. Sell-side analysts predict that Prestige Consumer Healthcare will post 2.76 earnings per share for the current fiscal year.
In related news, EVP Timothy Connors sold 34,000 shares of the firm’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $38.25, for a total transaction of $1,300,500.00. Following the sale, the executive vice president now owns 25,775 shares of the company’s stock, valued at $985,893.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.14% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of PBH. Great West Life Assurance Co. Can raised its stake in shares of Prestige Consumer Healthcare by 6.2% in the fourth quarter. Great West Life Assurance Co. Can now owns 30,844 shares of the company’s stock worth $885,000 after purchasing an additional 1,795 shares during the last quarter. Polen Capital Management LLC raised its stake in shares of Prestige Consumer Healthcare by 47.1% in the fourth quarter. Polen Capital Management LLC now owns 10,570 shares of the company’s stock worth $326,000 after purchasing an additional 3,382 shares during the last quarter. GSA Capital Partners LLP raised its stake in shares of Prestige Consumer Healthcare by 138.6% in the fourth quarter. GSA Capital Partners LLP now owns 35,300 shares of the company’s stock worth $1,090,000 after purchasing an additional 20,505 shares during the last quarter. Citigroup Inc. raised its stake in shares of Prestige Consumer Healthcare by 72.2% in the fourth quarter. Citigroup Inc. now owns 9,271 shares of the company’s stock worth $286,000 after purchasing an additional 3,887 shares during the last quarter. Finally, State of Tennessee Treasury Department purchased a new position in shares of Prestige Consumer Healthcare in the fourth quarter worth about $4,411,000.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare and household cleaning products in North America, Australia, and internationally. It operates in three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning.
Recommended Story: What Are Treasury Bonds?
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.